Citations

Mayo Clinic

Showing 10 of 108572 citations.

Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline
Bedrosian, Isabelle , Somerfield, Mark R. , Boughey, Judy C. , Curigliano, Giuseppe , Friedman, Sue , Kohlmann, Wendy , Kurian, Allison W. , Laronga, Christine , Norquist, Barbara M. , Plichta, Jennifer K. , Rodríguez, Patricia , Shah, Payal D. , Wood, Marie , Yadav, Siddhartha , Yao, Katherine , Boughey, JC , Curigliano, Giuseppe , Kohlmann, Wendy K , Kurian, Allison W , Lynce, Filipa , Norquist, Barbara , Plichta, Jennifer K , Rodriguez, Patricia , Shah, Payal D , Tischkowitz, Marc D. , Yadav, Siddhartha , Robson, Mark , Bedrosian, Isabelle , Achatz, Maria Isabel , Robson, Mark E.

Journal of Clinical Oncology | January 4, 2024 | Volume: 42 | Issue: 5 | Pages: 584-604

10.1200/jco.23.02225 | PMID 38175972 Get It

PURPOSE To develop recommendations for germline mutation testing for patients with breast cancer. METHODS An ASCO–Society of Surgical Oncology (SSO) panel convened to develop recommendations based on a systematic review and formal consensus process. RESULTS Forty-seven articles met eligibility criteria for the germline mutation testing recommendations; 18 for the genetic counseling recommendations. RECOMMENDATIONS BRCA1/ 2 mutation testing should be offered to all newly diagnosed patients with breast cancer ≤65 years and select patients >65 years based on personal history, family history, ancestry, or eligibility for poly(ADP-ribose) polymerase (PARP) inhibitor therapy. All patients with recurrent breast cancer who are candidates for PARP inhibitor therapy should be offered BRCA1/ 2 testing, regardless of family history. BRCA1/ 2 testing should be offered to women who develop a second primary cancer in the ipsilateral or contralateral breast. For patients with prior history of breast cancer and without active disease, testing should be offered to patients diagnosed ≤65 years and selectively in patients diagnosed after 65 years, if it will inform personal and family risk. Testing for high-penetrance cancer susceptibility genes beyond BRCA1/ 2 should be offered to those with supportive family histories; testing for moderate-penetrance genes may be offered if necessary to inform personal and family cancer risk. Patients should be provided enough pretest information for informed consent; those with pathogenic variants should receive individualized post-test counseling. Variants of uncertain significance should not impact management, and patients with such variants should be followed for reclassification. Referral to providers experienced in clinical cancer genetics may help facilitate patient selection and interpretation of expanded testing, and provide counseling of individuals without pathogenic germline variants but with significant family history. Additional information is available at www.asco.org/breast-cancer-guidelines .
Defining the Role of the Advanced Practice Provider Within the National Cancer Institute Community Oncology Research Program
Braun‐Inglis, Christa , Dressler, Emily V. , Myers, Jamie , Benson, Al B. , Flannery, Marie , Good, Marjorie J. , Denicoff, Andrea , Berenberg, Jeffrey L. , DeTroye, Alisha , O'Brien, Bridget, Kottschade, Lisa A. , Omatsu, Dee Ann, Foust, Melyssa , Lesser, Glenn J. , Braun-Inglis, Christa M , Myers, Jamie S , Good, Marjorie , Kottschade, Lisa A , Nightingale, Chandylen L , Dressler, Emily V , Kittel, Carol , Nightingale, Chandylen L.

JCO Oncology Practice | January 4, 2024 | Volume: 20 | Issue: 2 | Pages: 239-246

10.1200/op.23.00501 | PMID 38175992 Get It

PURPOSE Oncology advanced practice providers (APPs), including nurse practitioners, clinical nurse specialists, physician assistants, and clinical pharmacists, contribute significantly to quality cancer care. Understanding the research-related roles of APPs in the National Cancer Institute's (NCI) Community Oncology Research Program (NCORP) could lead to enhanced protocol development, trial conduct, and accrual. METHODS The 2022 NCORP Landscape Assessment Survey asked two questions about the utilization and roles of APPs in the NCORP. RESULTS A total of 271 practice groups completed the 2022 survey, with a response rate of 90%. Of the 259 nonpediatric exclusive practice groups analyzed in this study, 92% used APPs for clinical care activities and 73% used APPs for research activities. APPs most often provided clinical care for patients enrolled in trials (97%), followed by assistance with coordination (65%), presenting/explaining clinical trials (59%), screening patients (49%), ordering investigational drugs (37%), and consenting participants (24%). Some groups reported APPs as an enrolling investigator (18%) and/or participating in institutional oversight/selection of trials (15%). Only 5% of NCORP sites reported APPs as a site primary investigator for trials, and very few (3%) reported APPs participating in protocol development. CONCLUSION Practice groups report involving APPs in clinical research within the NCORP network; however, opportunities for growth exists. As team-based care has enhanced clinical practice in oncology, this same approach can be used to enhance successful research. Suggested strategies include supporting APP research-related time, recognition, and education. The findings of this survey and subsequent recommendations may be applied to all adult oncology practices that participate in clinical research.
Post-mortem examination of fatal acute type A aortic dissection: what does it teach us?
Karadzha, Anastasiia , Schaff, Hartzell V. , Frye, Robert L. , Bois, Melanie C. , Bagameri, Gabor, Greason, Kevin L. , Shrestha, Malakh , Shrestha, Malakh L, Schaff, Hartzell , Crestanello, Juan A.

European Journal of Cardio-Thoracic Surgery | January 4, 2024 | Volume: 65 | Issue: 1 | Pages: No page available

10.1093/ejcts/ezad432 | PMID 38175790 Get It

Abstract OBJECTIVES Acute type A aortic dissection (ATAAD) remains a highly life-threatening condition. This study investigates factors associated with fatal ATAAD prior to surgical treatment. METHODS We reviewed autopsy reports of ATAAD decedents who died before surgical intervention and underwent postmortem examination at our clinic from 1994 to 2022. RESULTS Among 94 eligible cases, 50 (53.2%) decedents had DeBakey type I dissection, and 44 (46.8%) had DeBakey type II dissection. Most were males, 63 (67%), and 72 (77%) had a history of hypertension. The median age was 70.5 years, and the type II group was a decade older than the type I group (P < 0.001). Decedents in the type II group predominantly died during the first hour after symptoms onset 16 (52%), while in the type I group, fatalities occurred between 1 h and 1 day, 27 (66%). The most common site of the intimal tear was the midportion of the ascending aorta, 45 (48%). The median ascending aorta size was 5 cm for the entire cohort, 5.2 cm for type I and 4.6 cm for type II (P < 0.045). CONCLUSIONS In this autopsy study of fatal acute aortic dissection, the median aortic size was below the current guideline threshold for elective repair. Type II acute aortic dissections were found more frequently than expected and were characterized by older age, advanced aortic atherosclerosis, smaller aortic size, a shorter interval from symptom onset to death and a higher frequency of syncope compared to type I dissection.
Persistent Tumor Mutational Burden (pTMB) May Predict Response to Immune Checkpoint Inhibitors
Smith, Katherine E. , Markovic, Svetomir N. , Smith, Katherine E R

Clinical Chemistry | January 4, 2024 | Volume: 70 | Issue: 1 | Pages: 25-26

10.1093/clinchem/hvad128 | PMID 38175581 Get It

Thrombolytic Therapy for Central Retinal Artery Occlusion in an Academic Multi-Site Stroke Centre
Alhayek, Nour, Sobczak, Jacob, Vanood, Aimen , O’Carroll, Cumara B. , Chen, John J. , Dumitrascu, Oana M. , Sobczak, Jacob M, Chen, John J , Dumitrascu, Oana M , Demaerschalk, Bart M.

Neuro-Ophthalmology | January 4, 2024 | Volume: 48 | Issue: 2 | Pages: 111-121

10.1080/01658107.2023.2290536 | PMID 38487357 Get It

Alport syndrome: A puzzling case of thrombocytopenia and giant unusual platelets in blood smear
Ocal, Jon , Sola‐Visner, Martha , Rimsza, Lisa M. , Rimsza, Lisa M

American Journal of Hematology | January 4, 2024 | Volume: 99 | Issue: 6 | Pages: 1168-1169

10.1002/ajh.27197 | PMID 38174980 Get It

Macrophage RAGE activation is proinflammatory in NASH
Parthasarathy, Gopanandan , Mauer, Amy S. , Golla, Naresh, Daniel, P. Vineeth , Kim, Lily H. , Sidhu, Guneet , rd, George W. Marek, Loeuillard, Emilien , Krishnan, Anuradha, Lee, Hyun Se Kim , Marek, George W, Kim Lee, Hyun Se , Daniel, P Vineeth , Pavelko, Kevin D. , Charlton, Michael , Hirsova, Petra , Ilyas, Sumera I. , Malhi, Harmeet

JCI Insight | January 4, 2024 | Volume: 9 | Issue: 3 | Pages: No page available

10.1172/jci.insight.169138 | PMID 38175729 Get It

Intrahepatic macrophages in nonalcoholic steatohepatitis (NASH) are heterogenous and include proinflammatory recruited monocyte-derived macrophages. The receptor for advanced glycation endproducts (RAGE) is expressed on macrophages and can be activated by damage associated molecular patterns (DAMPs) upregulated in NASH, yet the role of macrophage-specific RAGE signaling in NASH is unclear. Therefore, we hypothesized that RAGE-expressing macrophages are proinflammatory and mediate liver inflammation in NASH. Compared with healthy controls, RAGE expression was increased in liver biopsies from patients with NASH. In a high-fat, -fructose, and -cholesterol–induced (FFC)-induced murine model of NASH, RAGE expression was increased, specifically on recruited macrophages. FFC mice that received a pharmacological inhibitor of RAGE (TTP488), and myeloid-specific RAGE KO mice (RAGE-MKO) had attenuated liver injury associated with a reduced accumulation of RAGE + recruited macrophages. Transcriptomics analysis suggested that pathways of macrophage and T cell activation were upregulated by FFC diet, inhibited by TTP488 treatment, and reduced in RAGE-MKO mice. Correspondingly, the secretome of ligand-stimulated BM-derived macrophages from RAGE-MKO mice had an attenuated capacity to activate CD8 + T cells. Our data implicate RAGE as what we propose to be a novel and potentially targetable mediator of the proinflammatory signaling of recruited macrophages in NASH.
Introducing the Fellows’ Corner: Fostering Early Career Voices in Healthcare
Islam, Bianca N. , Tariq, Raseen , Tariq, Raseen

Inflammatory Bowel Diseases | January 4, 2024 | Volume: 30 | Issue: 11 | Pages: 2236-2237

10.1093/ibd/izad306 | PMID 38174729 Get It

The Tour de France, also possible for mortals? A comparison of a recreational and a World Tour cyclist
Muriel, Xabier , Joyner, Michael J. , DeSouza, Christopher A. , Valenzuela, Pedro L. , Joyner, Michael J , DeSouza, Christopher A , Valenzuela, Pedro L , Barranco‐Gil, David , Lucı́a, Alejandro

Journal of Applied Physiology | January 4, 2024 | Volume: 136 | Issue: 2 | Pages: 432-436

10.1152/japplphysiol.00798.2023 | PMID 38174376 Get It

This case report indicates that a recreationally trained 58-year-old man can reach similar or even higher values of energy expenditure (∼4 times their basal metabolic rate) than professional cyclists, who are likely near the ceiling of sustained energy expenditure for humans. This was possible owing to a total longer exercise time coupled with a lower absolute and relative intensity in the recreational athlete.
Response to Benson et al
Bali, Aman S. , Bali, Aman , Hashash, Jana G. , Farraye, Francis A.

American Journal of Gastroenterology | January 4, 2024 | Volume: 119 | Issue: 1 | Pages: 214-215

10.14309/ajg.0000000000002486 | PMID 38174915 Get It